XARELTO®: Dosing in initial treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)

Once-daily treatment after 21 days of twice-daily dosing

No dose adjustment based on weight

15 mg

For the first 21 days, twice daily with food, at the same time each day in patients with CrCl ≥15 mL/min

20 mg

Starting at day 22, once daily with food, at the same time each day for remaining treatment in patients with CrCl ≥15 mL/min

15 mg

For the first 21 days, twice daily with food, at the same time each day in patients with CrCl ≥15 mL/min

20 mg

Starting at day 22, once daily with food, at the same time each day for remaining treatment in patients with CrCl ≥15 mL/min

Renal Dose Consideration*†

  • Avoid using XARELTO® in patients with CrCl <15 mL/min

30-day Starter Pack for patients with DVT/PE

Image of XARELTO® packaging with starter dosageImage of XARELTO® packaging with starter dosage

Switch and Management

XARELTO® Dosing: All Indications

6 INDICATIONS

to treat and help protect from a VTE—both inpatient and outpatient‡1-7

XARELTO® VTE Platform

*Calculate CrCl based on actual weight.

†Patients with CrCl <30 mL/min were not studied, but administration of XARELTO® is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 mL/min to <50 mL/min).

‡The decision regarding initiation setting should be based on the prescriber's clinical judgment.

CrCl = creatinine clearance; DVT = deep vein thrombosis; PE = pulmonary embolism.

Previous: DVT/PE Safety Profile

References: 1. The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. 2. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. 3. Weitz JI, Lensing AWA, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211-1222. 4. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775. 5. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39. 6. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786. 7. Cohen AT, Spiro TE, Büller HR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-523.